Phase I Study of Bevacizumab, Everolimus, and Panobinostat (LBH-589) in Advanced Solid Tumors

PURPOSE: To define the maximum tolerated dose, clinical toxicities, and pharmacodynamics of bevacizumab, everolimus and panobinostat (LBH-589) when administered in combination in patients with advanced solid tumor malignancies. EXPERIMENT DESIGN: Subjects received 10 mg of panobinostat three times w...

詳細記述

保存先:
書誌詳細
主要な著者: Strickler, John H., Starodub, Alexander N., Jia, Jingquan, Meadows, Kellen L., Nixon, Andrew B., Dellinger, Andrew, Morse, Michael A., Uronis, Hope E., Marcom, P. Kelly, Zafar, S. Yousuf, Haley, Sherri T., Hurwitz, Herbert I.
フォーマット: Artigo
言語:Inglês
出版事項: 2012
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3793400/
https://ncbi.nlm.nih.gov/pubmed/22744359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1911-1
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料